NetworkNewsBreaks – Willow Biosciences Inc. (CSE: WLLW) Enters Joint Development Agreement with Noramco Inc.
Willow Biosciences Inc. (CSE: WLLW), a leading developer of biosynthetic production systems for plant-derived active pharmaceutical ingredients (APIs) and intermediates, in early June announced its entry into an exclusive joint development agreement with Noramco Inc., a leading manufacturer of cannabinoids. Per the update, the two firms intend to collaboratively develop a yeast-based biosynthesis platform for the production and distribution of cannabidiol. Willow further notes that the work conducted through the agreement has the potential to open new and larger markets for CBD and related compounds. “Noramco is a world-class organization with a long history of developing APIs across numerous markets…